Amrutanjan Healt

Is Amrutanjan Healt overvalued or undervalued?

As of May 14, 2025, Amrutanjan Health is considered undervalued with an attractive valuation grade despite a short-term underperformance against the Sensex, showing a PE ratio of 40.54 and strong long-term growth potential with a five-year return of 105.48%.

As of 14 May 2025, the valuation grade for Amrutanjan Healt has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 40.54, an EV to EBITDA ratio of 34.03, and a ROCE of 21.05%. In comparison to its peers, Sun Pharma has a PE of 35.25 and EV to EBITDA of 24.91, while Cipla shows a more attractive PE of 22.99 and EV to EBITDA of 15.93, highlighting Amrutanjan's relatively high valuation metrics.<BR><BR>Despite its attractive valuation grade, Amrutanjan has underperformed against the Sensex in the short term, with a year-to-date stock return of -1.37% compared to the Sensex's 5.63%. However, its long-term performance remains strong, with a five-year return of 105.48%. Overall, the company appears to be positioned well within the pharmaceuticals and biotechnology sector, suggesting potential for future growth.

Who are the top shareholders of the Amrutanjan Healt?

The top shareholders of Amrutanjan Health include Goodhealth Holdings Private Limited with 20.15%, mutual funds holding 7.55%, foreign institutional investors at 2.3%, and individual investors collectively owning 33.56%. The largest public shareholder is DSP Small Cap Fund with a 5.07% stake.

The top shareholders of Amrutanjan Health include a mix of promoters, mutual funds, and individual investors. The largest promoter is Goodhealth Holdings Private Limited, which holds 20.15% of the shares. In terms of institutional investment, mutual funds collectively hold 7.55% across four schemes, while foreign institutional investors (FIIs) hold 2.3% through 28 different entities. The highest public shareholder is DSP Small Cap Fund, with a 5.07% stake. Additionally, individual investors collectively hold 33.56% of the company's shares.

What does Amrutanjan Healt do?

Amrutanjan Health Care Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of bulk drugs and drug intermediates. As of March 2025, it reported net sales of ₹135 Cr and a net profit of ₹15 Cr, with a market cap of ₹2,071 Cr.

Overview: <BR>Amrutanjan Health Care Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the manufacture of bulk drugs and drug intermediates.<BR><BR>History: <BR>Amrutanjan Health Care Limited was incorporated on September 9, 1936, in Chennai, Tamil Nadu. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 135 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 15 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 2,071 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 41.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.64% <BR>Debt-Equity: -0.25 <BR>Return on Equity: 15.57% <BR>Price to Book: 6.41 <BR><BR>Contact Details: <BR>Address: New 103 Old 42-45 LuzChurch Rd, Mylapore Chennai Tamil Nadu : 600004 <BR>Tel: 91-44-24994164/24994465/24994366 <BR>Email: shares@amrutanjan.com <BR>Website: http://www.amrutanjan.com

Who are in the management team of Amrutanjan Healt?

As of March 2022, the management team of Amrutanjan Health includes S Sambhuprasad (CMD & Executive Director), five Independent Non-Executive Directors, Ramaa Prabhakar Arikirevula (Non-Executive Director), and M Srinivasan (Company Secretary & Compliance Officer). They oversee the company's operations and governance.

As of March 2022, the management team of Amrutanjan Healt includes the following individuals:<BR><BR>1. S Sambhuprasad - CMD & Executive Director<BR>2. Marie Shiranee Pereira - Independent Non-Executive Director<BR>3. V Raja - Independent Non-Executive Director<BR>4. Muralidharan Swayambunathan - Independent Non-Executive Director<BR>5. Meena Lochani Raghunathan - Independent Non-Executive Director<BR>6. Ramaa Prabhakar Arikirevula - Non-Executive Director<BR>7. M Srinivasan - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and governance.

Who are the peers of the Amrutanjan Healt?

Amrutanjan Healt's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. It has good management risk and capital structure, with a 1-year return of 6.53%, lower than Bajaj Healthcare's 85.57% but higher than Sigachi Indust.'s -17.65%.

Peers: The peers of Amrutanjan Healt are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Windlas Biotech, Sigachi Indust., Solara Active, Bajaj Healthcare, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Bajaj Healthcare, while Good management risk is found at Amrutanjan Healt, Torrent Pharma, and Windlas Biotech. Average management risk is noted at Sigachi Indust., while Below Average management risk is seen at Solara Active. For growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Amrutanjan Healt, Divi's Lab., Torrent Pharma, Windlas Biotech, Sigachi Indust., and Bajaj Healthcare. Excellent capital structure is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Amrutanjan Healt, Windlas Biotech, Sigachi Indust., while Good capital structure is found at Torrent Pharma, and Average capital structure is noted at Bajaj Healthcare and Solara Active.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bajaj Healthcare at 85.57%, while the peer with the lowest is Sigachi Indust. at -17.65%. Amrutanjan Healt's 1-year return of 6.53% is lower than Bajaj Healthcare's but higher than Sigachi Indust.'s. Additionally, Windlas Biotech, Sigachi Indust., and Solara Active have negative six-month returns.

How big is Amrutanjan Healt?

As of 24th July, Amrutanjan Health Care Ltd has a market capitalization of 2,001.00 Cr, with recent net sales of 451.82 Cr and net profit of 50.85 Cr over the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Amrutanjan Health Care Ltd has a market capitalization of 2,001.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 451.82 Cr, while the sum of Net Profit for the same period is 50.85 Cr.<BR><BR>Balance Sheet Snapshot: The latest annual period reported is March 2016, with Shareholder's Funds amounting to 108.74 Cr and Total Assets valued at 140.44 Cr.

How has been the historical performance of Amrutanjan Healt?

Amrutanjan Healt has demonstrated consistent growth in net sales and profits from 2011 to 2017, with net sales rising from 105.41 Cr to 231.70 Cr and profit after tax increasing from 10.43 Cr to 21.14 Cr, reflecting strong operational performance and improved financial stability.

Answer:<BR>The historical performance of Amrutanjan Healt shows a consistent growth trend in net sales and profits over the years, particularly from 2011 to 2017.<BR><BR>Breakdown:<BR>Amrutanjan Healt's net sales increased from 105.41 Cr in March 2011 to 231.70 Cr in March 2017, reflecting a strong upward trajectory. Other operating income also rose, contributing to total operating income growth from 105.41 Cr in 2011 to 234.59 Cr in 2017. The company's total expenditure, excluding depreciation, rose from 92.46 Cr in 2011 to 205.57 Cr in 2017, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) saw fluctuations, peaking at 36.34 Cr in March 2016 before slightly declining to 33.85 Cr in March 2017. Profit before tax increased from 15.60 Cr in 2011 to 33.24 Cr in 2017, while profit after tax reached 21.14 Cr in 2017, up from 10.43 Cr in 2011. The earnings per share (EPS) also improved from 3.44 in 2011 to 7.23 in 2017, demonstrating enhanced shareholder value. The company's total assets grew from 156.69 Cr in 2011 to 140.44 Cr in 2016, while total liabilities decreased from 30.80 Cr in 2011 to 2.50 Cr in 2016, indicating improved financial stability. Cash flow from operating activities increased significantly, showcasing the company's ability to generate cash from its operations, culminating in a closing cash balance of 42.42 Cr in March 2016. Overall, Amrutanjan Healt has shown a robust performance with increasing revenues and profits, alongside effective cost management.

Is Amrutanjan Healt technically bullish or bearish?

As of November 24, 2025, Amrutanjan Health's technical trend is mildly bearish, supported by bearish MACD readings, Bollinger Bands, and underperformance against the Sensex, despite some daily moving averages showing mild bullishness.

As of 24 November 2025, the technical trend for Amrutanjan Healt has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating mild bearishness, along with Bollinger Bands showing bearish signals in both time frames. The KST and Dow Theory also reflect a mildly bearish outlook on a weekly and monthly basis. Although daily moving averages are mildly bullish, the overall sentiment remains bearish due to the prevailing indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish stance.

When is the next results date for Amrutanjan Health Care Ltd?

The next results date for Amrutanjan Health Care Ltd is February 3, 2026.

The next results date for Amrutanjan Health Care Ltd is scheduled for February 3, 2026.

Are Amrutanjan Health Care Ltd latest results good or bad?

Amrutanjan Health Care Ltd's latest Q3 FY26 results are generally positive, with a 39.27% sequential increase in net profit and a 19.83% rise in revenue. However, the modest year-on-year profit growth and declining operating margins suggest potential challenges for long-term profitability.

Amrutanjan Health Care Ltd's latest results for Q3 FY26 can be characterized as generally positive, particularly in terms of sequential growth. The company reported a net profit of ₹19.45 crore, which represents a significant 39.27% increase compared to the previous quarter and a modest 1.04% increase year-on-year. Revenue also saw a strong uptick, reaching ₹141.04 crore, marking a 19.83% increase quarter-on-quarter and a 14.90% increase year-on-year.<BR><BR>The operating margin improved to 17.85%, up 381 basis points from the previous quarter, although it did decline by 116 basis points compared to the same quarter last year. This indicates that while the company is experiencing strong sales growth, there are challenges in maintaining profitability margins.<BR><BR>The seasonal nature of Amrutanjan's products, particularly pain relief and wellness items, contributed to this strong performance in the winter months. However, the modest year-on-year profit growth suggests that while the company is doing well in the short term, there may be underlying challenges affecting long-term profitability.<BR><BR>Overall, while the latest results show strong sequential performance, the year-on-year profit growth raises some concerns about the sustainability of this momentum. Investors should keep an eye on how the company navigates these challenges moving forward.

Should I buy, sell or hold Amrutanjan Health Care Ltd?

Has Amrutanjan Health Care Ltd declared dividend?

Yes, Amrutanjan Health Care Ltd has declared a 100% dividend, amounting to ₹1 per share, with an ex-date of February 6, 2026. While total returns have fluctuated, the company has shown positive returns over the 2 and 5-year periods.

Amrutanjan Health Care Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 1 per share<BR>- Ex-date: 06 Feb 26<BR><BR>Dividend Yield: 0.72%.<BR><BR>Total Returns by Period:<BR>In the 3 Months period, the price return was -12.24%, the dividend return was 0.28%, resulting in a total return of -11.96%.<BR><BR>In the 6 Months period, the price return was -8.61%, the dividend return was 0.70%, leading to a total return of -7.91%.<BR><BR>In the 1 Year period, the price return was -6.2%, the dividend return was 0.85%, resulting in a total return of -5.35%.<BR><BR>In the 2 Years period, the price return was 9.64%, the dividend return was 1.55%, leading to a total return of 11.19%.<BR><BR>In the 3 Years period, the price return was -10.97%, the dividend return was 2.35%, resulting in a total return of -8.62%.<BR><BR>In the 4 Years period, the price return was -24.41%, the dividend return was 2.20%, leading to a total return of -22.21%.<BR><BR>In the 5 Years period, the price return was 21.73%, the dividend return was 4.04%, resulting in a total return of 25.77%.<BR><BR>Overall, Amrutanjan Health Care Ltd has declared a significant dividend, and while the total returns have varied across different periods, the company has shown positive total returns over the longer 2, 5-year periods despite some negative returns in shorter durations.

Why is Amrutanjan Health Care Ltd falling/rising?

As of 16-Mar, Amrutanjan Health Care Ltd's stock price is at 528.05, down 2.93%, and has hit a new 52-week low of Rs 522.15. The stock has consistently underperformed, with a year-to-date decline of 20.97% and reduced investor interest, indicating a bearish trend.

As of 16-Mar, Amrutanjan Health Care Ltd's stock price is falling, currently at 528.05, which reflects a decrease of 15.95 or 2.93%. The stock has been on a downward trend, having lost 5.04% over the last three days and underperformed its sector by 1.81% today. Additionally, it hit a new 52-week low of Rs 522.15 during intraday trading, indicating significant selling pressure.<BR><BR>The stock's performance over various periods further illustrates its decline, with a year-to-date drop of 20.97% compared to a 11.40% decline in the Sensex. Over the past month, the stock has decreased by 12.95%, while the Sensex fell by 9.34%. This consistent underperformance is compounded by the fact that the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend.<BR><BR>Investor participation has also waned, with delivery volume falling by 17.5% against the 5-day average, indicating reduced interest from investors. Despite some positive factors, such as high management efficiency and a low debt-to-equity ratio, the stock's recent performance and declining investor engagement contribute to its current downward trajectory.

Which are the latest news on Amrutanjan Healt?